Pharmaceutical News

RSS

Intensive early treatment slows down progression of type 2 diabetes

Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

28 Jun 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Touch important for side-effects of medicines for premature babies with respiratory problems

Discovering that touch is important for the side-effects of a medicine for premature babies with respiratory problems. This is what Sanne Claessens finds so fascinating about fundamental research in medical pharmacology. PhD defence 27 June.

28 Jun 2012

Phototron launches new SG Sensors-brand sensors and controllers, growers

Phototron Holdings, Inc., a leading technology supplier to the hydroponic growing industry, today announced that its wholly owned SG Sensors division launched beta testing for its state-of-the-art wireless sensors and controllers, designed for growers of all sizes in the medicinal marijuana industry.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

OCC members praise FDA approval of new obesity drug – Belviq

Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

28 Jun 2012

Powerful new technique can manipulate the building-block molecules of organic chemistry

Scientists at The Scripps Research Institute have developed a powerful new technique for manipulating the building-block molecules of organic chemistry. The technique enables chemists to add new functional molecules to previously hard-to-reach positions on existing compounds-making it easier for them to generate new drugs and other organic chemicals.

28 Jun 2012

New compound could treat certain types of genetic disorders in muscles

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

28 Jun 2012

Gilead submits elvitegravir NDA with FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults.

28 Jun 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012

Diet enriched with curcumin and DHA can promote neuroprotection in chronic SCI

Researchers from the Department of Neurosurgery at the David Geffen School of Medicine and the Department of Integrative Biology and Physiology at UCLA have found that a diet enriched with docosahexaenoic acid (DHA), an omega-3 fatty acid, and curcumin, a component of the Indian spice turmeric, can protect the injured spinal cord and minimize the clinical and biochemical effects of spinal cord myelopathy in rats.

27 Jun 2012

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.

27 Jun 2012

USA Today features Q&A on Truvada's potential as prevention tool

USA Today features a Q&A on Truvada, an antiretroviral drug that a Food and Drug Administration (FDA) panel in May recommended be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus.

27 Jun 2012

DHA and curcumin preserve walking ability in rats with spinal-cord injury

UCLA researchers discovered that a diet enriched with a popular omega-3 fatty acid and an ingredient of curry spice preserved walking ability in rats with spinal-cord injury. Published June 26 in the Journal of Neurosurgery: Spine, the findings suggest that these dietary supplements help repair nerve cells and maintain neurological function after degenerative damage to the neck.

27 Jun 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Talyst launches new AutoPack for oral solid medications

Talyst, a leader in pharmacy automation, announces its newest AutoPack, which automates packaging for oral solid medications.

27 Jun 2012

Study: Fertility drug-conceived children are shorter on average

Among children born full term, those conceived with the help of fertility drugs are slightly shorter than naturally conceived children but overall are physically healthy, a new study finds. Results of the study will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Metformin reduces overall cancer risk in patients with Type 2 diabetes

A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

SmartTots announces recipients of inaugural round of research grants

SmartTots announced Robert Block, PhD and Caleb Ing, MD as the recipients of its inaugural round of research grants today. The research grants are intended to support investigations into the existence of a clinical signal suggesting poor neurocognitive outcomes as the result of early exposure to anesthesia. Drs. Block and Ing will be conducting separate studies both centered around determining the effects of anesthetics on early brain development. Both recipients will receive $100,000 to fund their studies.

26 Jun 2012

Vitamin D therapy may improve symptoms of depression in women

Women with moderate to severe depression had substantial improvement in their symptoms of depression after they received treatment for their vitamin D deficiency, a new study finds. The case report series will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012